viewCellmid Limited

Cellmid's Japanese shopping channel sale sets revenue record of $1.14 million

Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products.

Laboratory work
Cellmid is a life sciences company

Cellmid Ltd (ASX:CDY) has set another sales record after its second sales event this financial year on Japanese television shopping channel QVC delivered revenue of $1.14 million.

This is up from $1.1 million at a similar sales event in December 2018.

These highest ever retail sales of Cellmid’s Jo-Ju® branded hair products have confirmed the brand as one of the best performers of the QVC channel.

Shares up 32%

Investors responded positively with shares up to 27 cents intra-day, a 32% increase on yesterday's close.

The company is undertaking an audit with preliminary analysis of results indicating that sales for the fourth quarter of FY19 are also at a record high of $2.45 million – the highest ever quarterly result for the company.

This is compared to the 2018 quarter four total of $1.34 million.


Cellmid chief executive officer Maria Halasz said: “Our recent investment in expanding our senior leadership team and building our marketing capabilities is now translating through to increased sales and new distribution partnerships.

“We enter the 2020 financial year with positive operational momentum in sales growth and e-commerce expansion across Australia, the US and Japan.”

READ: Cellmid évolis professional product range to be sold in Europe

Cellmid is now preparing to launch its new e-commerce platform for its premium product range, évolis Professional, in Japan later this month.

The company has seen a ramp-up in its online performance since the launch of the new évolis website in Australia and the US in March 2019 and is confident that this success can be replicated in Japan in 2020.

READ: Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

Cellmid recently appointed Bart Wuurman as chief executive officer of its wholly-owned subsidiary Lyramid with the aim of unlocking shareholder value by separating the consumer health and biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

Wuurman has successfully executed biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale.

Quick facts: Cellmid Limited

Price: 0.093 AUD

Market: ASX
Market Cap: $11.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...


Cellmid expects to see strong revenue growth out of China ahead of...

Cellmid Ltd’s (ASX:CDY) Maria Halasz speaks to Proactive's Andrew Scott following the news it's received the first order from Ourui Health Management Limited (OHM) for the sale of its Japanese, Ju-Ju® and Lexilis® branded, anti-ageing hair and skincare products in China. The first order of...

on 27/1/21

2 min read